Latest News - ThromboGenics

Wednesday, May 24, 2017 | Conferences, ThromboGenics

ThromboGenics to present THR-317 Preclinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group Meeting

ThromboGenics announced that it will give a presentation at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting, which is being held in Budapest, Hungary…

Read the full story

Tuesday, May 02, 2017 | Conferences, ThromboGenics

New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 in Baltimore

ThromboGenics announced that its research and development team, associated experts and others will be presenting 12 papers and posters including new ophthalmic research findings at the upcoming ARVO (…

Read the full story

Friday, April 21, 2017 | Partnerships, Retina, ThromboGenics

Bicycle Therapeutics Announces a Candidate Preclinical Milestone in Its Ophthalmology Alliance with ThromboGenics

Bicycle Therapeutics announced the receipt of a preclinical milestone in connection with the advancement of a Bicycle into preclinical development for the treatment of diabetic macular edema, under it…

Read the full story

Tuesday, January 10, 2017 | Clinical Trials, ThromboGenics

ThromboGenics Enrolls First Patients in Phase 2 Clinical Study Evaluating THR-317 (anti-PlGF) for Diabetic Macular Edema (DME)

ThromboGenics NV announced the enrollment of the first patients in a phase 2, single-masked, multicenter exploratory study evaluating the safety and efficacy of 2 dose levels of THR-317 for the treatm…

Read the full story

Monday, August 08, 2016 | Clinical Trials, Retina, ThromboGenics

ThromboGenics 2-Year OASIS Study Results Published in Ophthalmology

ThromboGenics announced that the results from its 2 Year OASIS phase 3b study with Jetrea (ocriplasmin) have been published in the journal Ophthalmology. The OASIS study was a phase 3b randomized, …

Read the full story

Wednesday, January 13, 2016 | Clinical Trials, Retina, ThromboGenics

ThromboGenics Enrolls First Patient in Phase 2 CIRCLE Trial

ThromboGenics NV announced that the first patient has been enrolled in its phase 2 CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous…

Read the full story

Thursday, November 12, 2015 | Clinical Trials, ThromboGenics

ThromboGenics Announces FDA Acceptance of IND Application for Phase 2 Study with Jetrea for the Treatment of Non-Proliferative Diabetic Retinopathy

ThromboGenics NV announced that the FDA has accepted its investigational new drug (IND) application for its CIRCLE study, a phase 2, randomized, double-masked, sham-controlled, multicenter study…

Read the full story